Status:

RECRUITING

A Clinical Study of the TSX Dental Implant System (Xpresso)

Lead Sponsor:

ZimVie

Conditions:

Tooth Loss

Eligibility:

All Genders

18+ years

Brief Summary

A prospective, observational, multicenter study where 62 patients needing implants in the maxilla or mandible will be enrolled. The patients will be restored with a final prosthesis no later than 4 mo...

Detailed Description

This will be a prospective, observational, multicenter study. All implants will be placed in the maxilla or mandible. The patient will either have a temporary prosthesis placed (out of occlusion) imme...

Eligibility Criteria

Inclusion

  • Patients at least 18 years of age
  • Patients for whom a decision has already been made to use a dental implant in an edentulous or immediately removed tooth site to be fully restored in the mandible or maxilla.
  • Site planned for immediate extraction and immediate restoration should have intact bony walls- Type I (as described in Special Procedures section) sockets as verified by CBCT and during surgery; Type II may be considered at the discretion of the treating clinician
  • Previously extracted sites (healed at least 3-4 months)
  • For all sites, presence of opposing dentition (antagonist may be natural teeth or implant supported prosthesis) that will allow for functional occlusion is essential.
  • The site intended for implant placement should have at least 10mm of alveolar bone height and sufficient restorative space for a restoration; without the need for augmentation except for minor dehiscence, which can be augmented with autogenous bone chips and/or allograft (i.e.: Puros) to improve soft tissue attachment.
  • Patients must be physically able to tolerate conventional surgical and restorative procedures (IV sedation protocols may be used at the discretion of the treating clinician).
  • Patients who provide a signed informed consent.
  • Patients who agree to be evaluated for each study visit.

Exclusion

  • Patients with known systemic diseases such as diabetes, endocrine disease, heart disease, immuno-compromised, or mental disorders that are uncontrolled at the time of enrollment.
  • Patients with current use of bisphosphonates.
  • Patients with active infection or severe inflammation in the areas intended for treatment.
  • Patients with more than10 cigarette per day smoking habit.
  • Patients with a history of therapeutic radiation to the head or jaw.
  • Patients who are known to be pregnant at the screening visit or planning to become pregnant within 6 months of study enrollment.
  • Patients with evidence of untreated severe parafunctional habits such as bruxing or clenching.
  • Patients who have previously failed dental implants at the site intended for study implant placement
  • Patients with HIV or active Hepatitis infection.
  • Patients with a history of untreated generalized severe periodontitis.

Key Trial Info

Start Date :

April 24 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2027

Estimated Enrollment :

62 Patients enrolled

Trial Details

Trial ID

NCT06571812

Start Date

April 24 2024

End Date

June 1 2027

Last Update

November 19 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Ohio State University

Columbus, Ohio, United States, 43210

2

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104